New antibody drug GR2301 begins first human safety tests
NCT ID NCT07190716
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a single injection of GR2301, an antibody that targets IL15, in 36 healthy adults in China. The main goal is to check safety and how the body processes the drug. Participants are randomly assigned to receive either GR2301 or a placebo, and are monitored for at least 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GR2301 (IL15 monoclonal antibody)
- What this could lead to
- If successful, this early safety data could support further studies of GR2301 for immune-related diseases.
- What could go wrong
- This is a very early Phase 1 trial in only 36 healthy people, so it cannot yet show if the drug works for any disease. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children